Kyverna reports durable clinical responses and safety data for miv-cel
Kyverna Therapeutics released one-year positive data for its SPS and gMG trials, reinforcing its rolling BLA submission for miv-cel, a potential therapy for autoimmune diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed